Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aciclovir extended release - Vectans Pharma

Next Previous
Drug Profile

Aciclovir extended release - Vectans Pharma

Alternative Names: Aciclovir - Onxeo; Aciclovir extended release - Onxeo; Aciclovir Lauriad®; Aciclovir muco-adhesive buccal tablet - Onxeo; Acyclovir extended release - Onxeo; Acyclovir Lauriad® 50mg (Sitavir) - Onxeo; BA 021; Labiriad; Sitavig; Sitavir®

Latest Information Update: 09 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAlliance Pharma
  • Developer Cipher Pharmaceuticals; Vectans Pharma
  • Class Antivirals; Eye disorder therapies; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Herpes labialis

Highest Development Phases

  • Marketed Herpes labialis

Most Recent Events

  • 09 Aug 2022 Launched for Herpes labialis (Recurrent) in South Korea (Buccal), prior to August 2022
  • 09 Aug 2022 Navamedic expects to launch the drug in the Nordics and Benelux in the first half of 2024
  • 04 Aug 2022 Aciclovir extended release licensed to Navamedic for Herpes labialis in the Nordic and Benelux regions
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top